

EDITORIAL



Editor's welcome to the international journal of cardiovascular research and innovation

Peter A. McCullough, MD, MPH

Internal Medicine, Cardiology, Epidemiology Department, McCullough Foundation, United States

ARTICLE HISTORY

Received 02 September 2024; Revised 10 September 2024; Accepted 17 September 2024

Introduction

I want to sincerely thank the publisher and the editorial board for the honor of serving as editor-in-chief of the International Journal of Cardiovascular Research & Innovation. I have over four decades of experience as an author, reviewer, and editor in clinical practice as an internist, cardiologist, and epidemiologist holding degrees from Baylor University, University of Texas Southwestern Medical School, University of Michigan, and Southern Methodist University [1]. I have broadly published on a range of topics in medicine with > 1000 publications and > 700 citations in the National Library of Medicine. The Journal asked me to answer these questions for our readership.

Why did you select our Journal as your Platform?

The Journal presents a new opportunity with an innovative publisher unencumbered by mounting bureaucracy and conflict of interest with government agencies and corporations seeking to influence the flow of information to clinicians and the public on key advancements as well as safety concerns for patients with cardiovascular disease.

An Overview of our Journal, Including Its Scope and Significance in the Field.

International Journal of Cardiovascular Research & Innovation is appropriately named to seek authors and publications that represent cutting-edge research, new and important knowledge, and innovation that is non-obvious and challenging to existing paradigms in cardiovascular medicine. Timely reviews summarizing advancements and important analyses of large-scale population exposures and their contributions to cardiovascular syndromes will be heavily cited as touchstones for new investigative approaches for common problems holding hope or large public health impact.

Your Perspective on our Editorial Board (EB) Highlighting their Roles and Contributions

The nascent editorial board has done a wonderful job through the first year and the published papers stand as shining examples of proper peer review, editing, and final publication. The EB will be expanding over the next months to years to more fully represent the scope of the journal from basic to preclinical, to clinical research and innovation.

Future Goals for our Journal and Its Role in Advancing Cardiovascular Research.

The short-term goals include solicitation of high-quality manuscripts for peer review and publication in full issues and

volumes. Next, listing the major indexing services will be accomplished including the National Library of Medicine PUBMED. From that point we will see a rising number of citations, reads, downloads, and sharing that will result in a rising Impact Factor and other similar metrics.

Your Contributions Towards the Growth and Success of Our Journal

Initially, I plan to be involved with each and every submission. I will solicit high-quality papers from top authors around the world. Around the globe, the Journal of Cardiovascular Research & Innovation will quickly be known as a source of medical truth free from institutional, governmental, and industry bias.

I see the following as some of the largest issues facing cardiovascular research and its dissemination:

1. Confluence of metabolic and cardiorenal syndromes manifesting as cardiovascular disease [2],
2. Rapid pace of biotechnology for medical treatment of heart disease [3],
3. Balance of innovation, case selection, and risks/benefits of new operative procedures,
4. Recognition and management of iatrogenic conditions coming in large numbers after the pandemic.

In each of these areas, manuscripts must navigate threats to validity and arrive at conclusions supported by the data. We should all be wary of censorship and bias at the level of authors, their institutions, and publishers in this new age where propaganda terms such as "misinformation" "disinformation" and "infodemic" have crept into the medical literature [4]. No single person, institution, or journal holds agency over the truth declaring themselves as spreading "information" whereas an opponent is promulgating "misinformation." There are simply objective scientific observations and multiple interpretative points of view [5].

Likewise, propagandized dichotomies such as "science" and "anti-science" will be rejected as we embrace the scientific method and use it as a tool to generate new knowledge. Under my leadership, the peer-review process will be carried out at the highest level of integrity. Once fully peer-reviewed and published, a valid paper will not be retracted for political reasons or as a result of outside influence on the journal or its publisher. Retractions, which should be very rare, will follow the Committee

*Correspondence: Dr. Peter A. McCullough, MD, MPH, President, Internal Medicine, Cardiology, Epidemiology Department, McCullough Foundation, United States, Iran, e-mail: peteramccullough@gmail.com

on Publication Ethics (COPE) guidelines [6]. With these over-arching principles, I expect a rapid increase in submissions, publications, and indexing in the major listing services.

Conclusions

The future is very bright for academic medicine and progress is to be made against cardiovascular diseases. A new age of rapid dissemination of seminal reports positions our journal at a nexus in which we will serve a very important role as a publication source free of propagandized bias and influence by those who aim to achieve a power dynamic over others. Welcome to the International Journal of Cardiovascular Research & Innovation!

Disclosure Statement

The author declares no potential conflicts of interest.

References

1. McCullough PA, Roberts WC. Peter Andrew McCullough, MD, MPH: An Interview with the Editor. *Am J Card.* 2014;114(11): 1772-1785.
2. McCullough PA, Amin A, Pantalone KM, Ronco C. Cardiorenal nexus: a review with focus on combined chronic heart and kidney failure, and insights from recent clinical trials. *J Am Heart Assoc.* 2022;11(11):e024139. <https://doi.org/10.1161/JAHA.121.024139>
3. Rangaswami J, Bhalla V, De Boer IH, Staruschenko A, Sharp JA, Singh RR, et al. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association. *Circulation.* 2020;142(17):e265-286. <https://doi.org/10.1161/CIR.0000000000000920>
4. Germani F, Spitale G, Machiri SV, Ho CW, Ballalai I, Biller-Andorno N, Reis AA. Ethical Considerations in Infodemic Management: Systematic Scoping Review. *JMIR infodemiology.* 2024;4(1):e56307. <https://doi.org/10.2196/56307>
5. Dach J. Hypervaccination, Autism, ADHD and Neurodevelopmental Disorders. 2023. Available at: <https://jeffreychmd.com/2023/11/hypervaccination-autism-adhd-and-neurodevelopmental-disorders/>
6. Council CO. Ethics Toolkit for a Successful Editorial Office: A COPE Guide-English. 2022.